Please use this identifier to cite or link to this item:
|Title:||Hypocalcemia post denosumab in patients with chronic kidney disease stage 4-5.||Austin Authors:||Dave, Vatsa;Chiang, Cherie Ying;Booth, Jane;Mount, Peter F||Affiliation:||Department of Nephrology, Austin Health, Heidelberg, Melbourne, Victoria, Australia||Issue Date:||18-Mar-2015||Publication information:||American Journal of Nephrology 2015; 41(2): 129-37||Abstract:||Denosumab, a RANK-ligand inhibitor, is an effective treatment for osteoporosis in postmenopausal women and men. Unlike the bisphosphonates, it is not excreted by the kidney. Little is known, however, about its efficacy and safety in patients with severe chronic kidney disease (CKD).A retrospective study was performed in CKD 4-5D patients from a tertiary referral hospital who were treated with denosumab between 1st January 2011 and 31st March 2014. Data collected included information about the following: CKD stage, fracture history, bone mineral density, serum calcium levels pre and post denosumab treatment, episodes of hypocalcemia, relevant medications and adverse events.Eight patients with CKD-5 and 6 patients with CKD-4 were identified (all female, mean age 77.1 ± 9.9). The mean pre-denosumab calcium value was 2.42 ± 0.12 mmol/l, PTH 20.2 ± 14.7 pmol/l and 25-OH vitamin D 69.1 ± 30.1 nmol/l. After denosumab treatment, 6/8 patients with CKD-5/5D, and 2/5 patients with CKD-4 developed severe hypocalcemia. Two patients developed direct adverse complications of hypocalcemia (seizure, laryngospasm, prolonged QTc). Among the patients who developed hypocalcemia, the median time to serum calcium nadir was 21 days and the median time to correction of hypocalcemia was 71 days. Treatment of hypocalcemia required large doses of oral calcium and calcitriol, and increases in dialysate calcium concentration.A high rate of severe hypocalcemia was observed in patients with advanced CKD treated with denosumab. If denosumab is used in patients with severe CKD, close monitoring and aggressive replacement of calcium and calcitriol is required to avoid the development of hypocalcemia. © 2015 S. Karger AG, Basel.||Gov't Doc #:||25790847||URI:||http://ahro.austin.org.au/austinjspui/handle/1/12696||DOI:||10.1159/000380960||URL:||https://pubmed.ncbi.nlm.nih.gov/25790847||Type:||Journal Article|
|Appears in Collections:||Journal articles|
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.